OR WAIT null SECS
July 08, 2021
A remarkable run indeed, but cost questions can’t be ignored.
June 09, 2021
What are the reasons behind the slump and what does the future hold?
May 21, 2021
The recent flurry of Q1 earnings reports offer a unique opportunity to assess the real-time impacts of COVID-19 on the sector.
May 17, 2021
With a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.
May 11, 2021
Adding context to Pfizer’s orbit-busting, first-quarter earnings.
April 14, 2021
The “blank-check” method has emerged as a worthwhile bet for biopharma companies looking to raise capital and go public, but will its attractiveness fade along with the pandemic?
April 13, 2021
More capital gains and the potential strains for rest of 2021.
March 18, 2021
Report provides comprehensive look at financial and accounting issues faced by life sciences industry.
March 11, 2021
Examining the key biopharma stock numbers and industry trends from a year that challenged the conduct of business and market stability like never before.
Amid vaccine heroics, its complex story may finally be resonating.
